Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection

Studies show new deep-learning algorithm helps radiologists detect breast cancers in their early stages when used with the Genius^® 3D Mammography^™ exam*¹

MARLBOROUGH, Mass.–(BUSINESS WIRE)–#AI–Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced U.S. Food and Drug Administration (FDA) clearance and commercial availability of the Company’s Genius AI^™ Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.

The new technology represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius^® 3D Mammography^™ exam.*¹ The new technology highlights areas with subtle potential cancers that can be difficult to detect for further examination by the radiologist, and is designed to provide higher sensitivity and a false-positive rate much lower than Hologic’s previous generation CAD products.

“As the latest breakthrough in breast cancer screening, Genius AI Detection reinforces Hologic’s commitment to improving cancer detection, optimizing workflow and enhancing the patient experience across every step of the breast health care continuum,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “Not only did studies show that Genius AI Detection aids in image interpretation by highlighting suspicious, and often subtle, areas of interest, it also provides the radiologist the opportunity to prioritize the most concerning patient cases. This is a real game changer as it has the potential to shorten the cycle between screening and diagnostic follow-up, and ultimately improve patient outcomes.”

The new software delivers key metrics at the time of image acquisition to help radiologists categorize and prioritize cases by complexity and expected read time in order to optimize workflow and expedite patient care. It is the only deep learning product on the market that runs on the acquisition workstation of the mammography system without the need for a separate server, providing a simple, convenient and secure environment.

The Genius AI Detection software is the only 3D CAD solution that supports Hologic’s latest innovations in tomosynthesis imaging, Clarity HD™ and 3DQuorum™ imaging technology, in addition to standard-resolution tomosynthesis. To learn more, visit https://www.hologic.com/GeniusAI-Detection.

The Genius^® 3D Mammography^™ exam is acquired on the Hologic^® 3D Mammography^™ system and consists of a 2D and 3D^™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D^™ image set. The Genius exam is only available on the Hologic^® 3D Mammography^™ system.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, 3D, 3D Mammography, 3DQuorum, Genius, Genius AI and Hologic Clarity HD are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic breast cancer detection products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

*Based on analyses that do not control type I error and therefore cannot be generalized to specific comparisons outside this particular study. In this study: The average observed reader sensitivity for cancer cases was 75.9% with CAD and 66.8% without CAD. The difference in observed sensitivity was +9.0% (99% CI: 6.0%, 12.1%).

1. FDA Clearance: K201019

SOURCE: Hologic, Inc.

Contacts

Media Contact:
Jane Mazur

508.263.8764 (direct)

585.355.5978 (mobile)

jane.mazur@hologic.com

Investor Contact:
Michael Watts

858.410.8588

michael.watts@hologic.com